期刊
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
卷 46, 期 8, 页码 968-976出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.ijom.2017.03.001
关键词
prognostic biomarker; ACTN4; early stage oral tongue cancer; gene amplification
资金
- Practical Research for Innovation Cancer Control from the Japan Agency for Medical Research and Development (AMED) [15ck0106101h0002]
- AMED [16cm0106403h0001]
- AMED CREST-AMED
- Ministry of Education, Culture, Sports, Science and Technology of Japan (METX)
Despite complete resection of the early stage of oral tongue cancer by partial glossectomy, late cervical lymph node metastasis is frequently observed. Gene amplification of ACTN4 (protein name: actinin-4) is closely associated with the metastatic potential of various cancers. This retrospective study was performed to demonstrate the potential usefulness of ACTN4 gene amplification as a prognostic biomarker in patients with stage I/II oral tongue cancer. Fifty-four patients with stage I/II oral tongue cancer were enrolled retrospectively, in accordance with the reporting recommendations for tumour marker prognostic studies (REMARK). guidelines. The copy number of ACTN4 and the protein expression of actinin-4 were evaluated by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), respectively. The overall survival time of patients with gene amplification of ACTN4 was significantly shorter than that of patients without gene amplification (P = 0.0010, log-rank test). Gene amplification of ACTN4 was a significant independent risk factor for death in patients with stage I/II oral tongue cancer (hazard ratio 6.08, 95% confidence interval 1.66-22.27). Gene amplification of AETN4 is a potential prognostic biomarker for overall survival in oral tongue cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据